Abstract
Oscar Health, Inc. is scheduled to report quarterly results on May 6, 2026 Pre-Market, and this preview synthesizes the latest financial estimates, last quarter’s performance, management commentary, and recent analyst views to frame the setup into the print.Market Forecast
Consensus anticipates that Oscar Health, Inc. will deliver revenue of 4.92 billion US dollars for the current quarter, implying 71.80% year-over-year growth, with EPS at $1.18, up 49.36% year-over-year; EBIT is projected at 448.18 million US dollars, up 76.08% year-over-year. Forecasts for gross margin and net margin have not been disclosed, while the revenue and earnings projections suggest a pivot toward operating profitability and improved cost leverage versus the prior year.The company’s core premium-driven business is expected to benefit from membership growth and rate actions that carried into the new plan year, while unit-cost management and administrative discipline remain crucial to sustaining earnings expansion across 2026. The most promising incremental growth vector is the newly launched Lucie Health Marketplace, positioned to broaden product breadth and broker engagement; near-term revenue contribution is nascent, with performance to be monitored through adoption and placements this quarter.
Last Quarter Review
In the preceding quarter, Oscar Health, Inc. generated 2.81 billion US dollars in revenue (up 17.25% year-over-year), with a gross profit margin of 6.60%, a GAAP net loss attributable to the company of 353.00 million US dollars, a net profit margin of -12.57%, and adjusted EPS (per the tool’s EPS measure) of -$1.24 (down 100% year-over-year).A key financial highlight was the year-over-year revenue expansion despite a widened loss per share, underscoring top-line resilience into year-end alongside near-term pressure from medical and operating costs. In its revenue mix, premiums before ceded reinsurance represented about 98.02% of the period’s breakdown and 11.47 billion US dollars in value per the tool’s categorization, while investment income was 202.94 million US dollars and services and other were 28.59 million US dollars; year-over-year mix dynamics were not disclosed.
Current Quarter Outlook
Main business: premium-driven core performance and operating leverage
The central narrative for this quarter is whether Oscar Health, Inc. can translate strong top-line growth into operating leverage, consistent with forecasts calling for 4.92 billion US dollars in revenue and 448.18 million US dollars in EBIT. The EPS estimate of $1.18 signals a swing in per-share profitability against last quarter’s loss, implying lower medical costs relative to premium yield and tighter expense control. These estimates implicitly assume a constructive claims environment and benefits from pricing and product design implemented for the current plan year. A key operating variable is the relationship between premium rates, risk adjustment accruals, and medical utilization. While seasonality and early-year dynamics can push claims volatility, the magnitude of the modeled EBIT improvement suggests that pricing and unit cost containment are tracking toward internal targets. Administrative cost discipline also matters; even modest improvements in non-medical expense ratios can amplify the pass-through of premium growth to EBIT, given the revenue scale implied by consensus. With forecasts tracking strong year-over-year revenue expansion, investors will scrutinize how much of that Delta translates into margins, particularly as the company cycles elevated loss ratios and the prior quarter’s net margin of -12.57%. Within the main business lines, premiums before ceded reinsurance remain the dominant revenue source. The revenue mix captured by the latest breakdown—approximately 98.02% premiums, 1.73% investment income, and 0.24% services and other—highlights the degree to which net earnings are sensitive to claims trends and pricing adequacy. Execution points to watch into the print include: premium yield versus medical cost trend, the pacing of accruals, and any commentary on plan-level performance and the trajectory of operating expenses as membership scales.Most promising business: Lucie Health Marketplace and embedded cross-sell economics
Oscar Health, Inc. introduced the Lucie Health Marketplace in April, an integrated digital storefront connecting consumers and brokers to individual medical plans and supplemental coverage products. While contribution in the current quarter is likely modest, the platform can enhance customer acquisition efficiency, drive cross-sell into dental, vision, and hospital care policies, and help Oscar convert broker workflows into recurring placements and renewals. For the near term, the economically relevant metrics will be broker onboarding, quote-to-bind conversion, user growth, and the emerging take rate from supplemental products. The strategic relevance of the Marketplace is twofold. First, it broadens the distribution reach, enabling fixed healthcare budgets and tax-advantaged accounts that allow employers to fund coverage while members choose plans suited to their needs. Second, it helps diversify revenue beyond core medical premiums over time, particularly if Oscar can capture incremental economics from ancillary products. For this quarter, the pathway to measurable revenue is about seeding adoption: end-market breadth, carrier inventory, and platform stickiness. The company’s guidance framework for 2026 revenue (18.70–19.00 billion US dollars) reinforces that the core engine is premium growth; the Marketplace is designed to compound that growth by lowering friction for brokers and members and by increasing product density per customer over subsequent periods.Key stock drivers this quarter: claims behavior, pricing yield, and expense discipline
Share performance into and out of earnings will hinge on the balance of premium yield versus medical cost trend and on how that balance flows through to EPS. With consensus calling for a 76.08% year-over-year rise in EBIT and a 49.36% year-over-year increase in EPS, upside depends on demonstrating that claims seasonality is tracking within expectations and that rate actions are sufficient to cover unit-cost inflation. Any disclosure around reserve development, plan-level profitability, or updated views on the current year medical cost trajectory will be pivotal to the sustainability of the earnings bridge. Pricing execution remains central. Management has indicated that products for the current coverage year were designed and priced for adversity, signaling a bias toward protecting margins if utilization runs hot. The degree to which such positioning appears in quarterly results—via margin resilience or favorable commentary on pricing adequacy—may inform how investors recalibrate full-year profit expectations. Additionally, operating expenses can be a swing factor; as revenue scales, incremental margin capture depends on whether the cost base grows more slowly than premiums. Clear evidence of non-medical expense efficiency and technology leverage would increase confidence in the durability of the projected earnings profile. Finally, while investment income and services are minor in the revenue mix, they can complement earnings in a quarter with robust premium flows. Lower variability in these line items supports cleaner translation from revenue to operating profit. Investors will likely look for management color on capital position, cash generation, and the pacing of any reinvestments into growth initiatives, including the Marketplace, to assess the balance between near-term profitability and longer-term platform expansion.Analyst Opinions
Across recent opinions published between January and April, the balance of views tilts bullish. Among major actions captured in this period, there are two bullish calls (Raymond James and Piper Sandler), one bearish call (Wells Fargo), and two neutral stances (UBS and Jefferies), yielding a bullish-to-bearish ratio of 2:1. The majority perspective emphasizes improving margins and better risk management heading into 2026, with a focus on operating leverage from premium growth and disciplined pricing.Raymond James upgraded Oscar Health, Inc. to Outperform with an 18.00 US dollars price target, highlighting the company as a relative standout as margins recover across the exchange market. The thrust of the upgrade centers on improved visibility into profitability drivers, supported by a product portfolio designed to preserve margin even under challenging utilization conditions. Their case aligns with the current quarter’s consensus profile—revenue up 71.80% year-over-year and EBIT up 76.08% year-over-year—suggesting meaningful operating leverage if claims behavior remains within planned ranges. In practical terms, the firm is watching for evidence that premium increases and benefit designs are translating into sustained margin gains, rather than one-off quarterly improvements.
Piper Sandler upgraded the stock to Overweight, stressing execution and the notion that current-year products are “designed and priced for adversity.” This supports a thesis where downside from cost volatility is contained, and upside flows through as pricing aligns with utilization. The firm’s constructive stance implies confidence not only in premium yield and medical management but also in the scalability of the company’s operating model, including the evolving role of technology in lowering administrative burden and improving care navigation. For the current quarter, Piper’s framework implies that beats on EPS or EBIT would be driven by better-than-expected medical cost ratios and disciplined non-medical expense growth, consistent with the consensus calling for $1.18 in EPS and 448.18 million US dollars in EBIT.
While not included in the bullish count, two neutral moves—Jefferies raising the rating to Hold with a price target of 16.00 US dollars and UBS maintaining Neutral with a 15.00 US dollars target—provide additional context. Both acknowledge progress while waiting for clearer confirmation that margin improvements can be maintained through the year. In contrast, Wells Fargo maintained a Sell with an 11.00 US dollars target, reflecting caution around valuation and execution risks. The majority view nevertheless leans toward improved profitability in the near term, expecting that rate adequacy, claims management, and expense control will underpin a constructive earnings path.
In sum, the prevailing institutional view anticipates that Oscar Health, Inc. will convert strong top-line growth into meaningfully better earnings this quarter. Attention will focus on the alignment of premium yield with medical cost trend, the fidelity of pricing assumptions in the early months of the plan year, and signals that operating expense leverage is taking hold. Positive confirmation on these points would reinforce the bullish stance and could support upward revisions to full-year profitability expectations against the backdrop of management’s 2026 revenue framework of 18.70–19.00 billion US dollars.